Deals in Depth: March 2010
GSK penned a $563 million deal with Cellzome for rights to the latter's epigenetics platform. Leading M&A was Teva's $4.5 billion bid for ratiopharm. Biopharma financing dollars rebounded, with notable private transactions including Archimedes's $100 million venture financing, and a $75 million PIPE that Lexicon did concurrent with a $111 million follow-on. Mindray's $151 million FOPO was responsible for over half of all device dollars.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.